drugset / Trial / NCT04601935
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, single-center, open-label dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCX cells in subjects with relapsed/refractory multiple myeloma
Timeline
- Start
- 2020-10-09
- Primary completion
- 2023-01
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-BCX | Cell therapy | 0.25 cells/kg | — |
| Subject | LCAR-BCX | Cell therapy | 0.5 cells/kg | — |
| Subject | LCAR-BCX | Cell therapy | 1 cells/kg | — |
| Subject | LCAR-BCX | Cell therapy | 2 cells/kg | — |
| Subject | LCAR-BCX | Cell therapy | 4 cells/kg | — |